Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Portföljen: Så många aktier bör du ha i portföljen – Hernhags VM-elva träffar mitt i prick

Pressmeddelanden från Faron Pharmaceuticals

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts
Idag 08:00
Faron Pharmaceuticals
Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS11 jun 16:05
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY11 jun 16:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of Treasury Shares10 jun 18:45
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY08 jun 18:30
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY05 jun 12:50
Faron Pharmaceuticals
Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee04 jun 14:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY03 jun 13:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of New Shares03 jun 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds01 jun 14:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY28 maj 15:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY28 maj 14:35
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company28 maj 14:30
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds18 maj 08:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY13 maj 08:00
Faron Pharmaceuticals
Faron to present new BEXMAB translational and clinical data in HR-MDS at EHA 202606 maj 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service05 maj 09:30
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY05 maj 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Directorate Appointment04 maj 13:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting30 apr 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Issuance of warrants22 apr 13:30
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY20 apr 09:15
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY20 apr 09:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY16 apr 17:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY16 apr 08:00
Faron Pharmaceuticals
Faron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDS14 apr 14:15
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register14 apr 09:45
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of New Shares13 apr 13:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds10 apr 15:30
Faron Pharmaceuticals
NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING10 apr 14:55
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register09 apr 19:25
Faron Pharmaceuticals
Faron publishes final results of its EUR 40.1 million rights issue08 apr 16:15
Faron Pharmaceuticals
Inside Information: Faron publishes preliminary results of its successful rights issue31 mar 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director Dealing26 mar 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities25 mar 09:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director Dealing24 mar 17:30
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY19 mar 08:10
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director Dealing19 mar 08:05
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director Dealing19 mar 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director Dealing12 mar 15:30
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY11 mar 19:20
Faron Pharmaceuticals
The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus11 mar 09:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY10 mar 08:48
Faron Pharmaceuticals
Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway09 mar 18:45
Faron Pharmaceuticals
Update to Faron’s Financial Calendar and date of the Annual General Meeting in 202604 mar 17:45
Faron Pharmaceuticals
Correction: Faron Pharmaceuticals Ltd’s Annual Report 2025 published04 mar 08:15
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd’s Annual Report 2025 published04 mar 08:00
Faron Pharmaceuticals
Faron’s Financial Statements Release 1 January to 31 December 202502 mar 11:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting02 mar 08:00
Faron Pharmaceuticals
Faron and City of Hope in process of developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS23 feb 08:00
Faron Pharmaceuticals
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 202619 feb 08:00
Faron Pharmaceuticals
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML09 feb 18:45
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING09 feb 18:35
Faron Pharmaceuticals
Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones03 feb 17:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of New Shares03 feb 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds29 jan 08:00
Faron Pharmaceuticals
New review published in Immunotherapy highlights the potential for Clever-1 inhibition with bexmarilimab to become the cornerstone of next-generation, multi-indication cancer immunotherapy27 jan 08:00
Faron Pharmaceuticals
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma13 jan 17:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: PDMR Dealing08 jan 18:45
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds22 dec 2025 08:00
Faron Pharmaceuticals
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer17 dec 2025 15:30
Faron Pharmaceuticals
Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board11 dec 2025 09:30
Faron Pharmaceuticals
Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement08 dec 2025 08:00
Faron Pharmaceuticals
Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile04 dec 2025 17:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Holding(s) in Company03 dec 2025 11:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of New Shares03 dec 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds02 dec 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Grant of Options01 dec 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Appointment of CFO27 nov 2025 08:00
Faron Pharmaceuticals
Faron’s Financial Calendar for 202624 nov 2025 18:15
Faron Pharmaceuticals
INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT04 nov 2025 08:00
Faron Pharmaceuticals
Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy03 nov 2025 08:00
Faron Pharmaceuticals
Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment28 okt 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds21 okt 2025 15:10
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY20 okt 2025 08:00
Faron Pharmaceuticals
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients03 okt 2025 12:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of New Shares03 okt 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds19 sep 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity12 sep 2025 17:25
Faron Pharmaceuticals
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 202527 aug 2025 08:00
Faron Pharmaceuticals
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 202519 aug 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results18 aug 2025 08:00
Faron Pharmaceuticals
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA08 aug 2025 16:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Holding(s) in Company08 aug 2025 09:30
Faron Pharmaceuticals
Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted07 aug 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds06 aug 2025 08:00
Faron Pharmaceuticals
Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%30 jul 2025 08:30
Faron Pharmaceuticals
FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 202509 jul 2025 08:00
Faron Pharmaceuticals
Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 202502 jul 2025 12:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director Dealing30 jun 2025 13:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director/PCA Dealing30 jun 2025 08:00
Faron Pharmaceuticals
Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action12 jun 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 202505 jun 2025 17:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation03 jun 2025 13:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Registration of New Shares03 jun 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds02 jun 2025 08:00
Faron Pharmaceuticals
Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 202530 maj 2025 08:00
Faron Pharmaceuticals
Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology27 maj 2025 18:00
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company27 maj 2025 08:00
Faron Pharmaceuticals
Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies23 maj 2025 08:00
Faron Pharmaceuticals
Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab